Agios Plunges 49% as Phase 3 Sickle Cell Data and Institutional Stakes Take Center Stage
By ATTN Desk · Editorial oversight: Sean Han
Introduction
Agios Pharmaceuticals Inc. (NASDAQ: AGIO) is a Cambridge, Massachusetts–based biopharmaceutical company specializing in therapies for genetically defined and rare diseases. Since its initial public offering in July 2013, Agios has focused on research in cellular metabolism, particularly in the areas of hemolytic anemias and metabolic oncology.
Corporate Structure
Founded in 2008 by Lewis Cantley, Tak Mak, and Craig Thompson, Agios operates as a Delaware corporation. The company employs between 501 and 1,000 people at its headquarters and satellite offices. Brian Goff has been serving as Chief Executive Officer since August 2022. Agios’ common stock is traded on the NASDAQ Global Select Market under the ticker AGIO (CIK: 0001439222).
Biopharmaceuticals by little plant
Recent Developments and News
On October 30, 2025, Agios filed its Form 10-Q for the quarter ended September 30, 2025, and concurrently released third-quarter financial results and business highlights. On November 14, 2025, a Schedule 13G/A amendment disclosed that Paradigm BioCapital Advisors LP, Paradigm BioCapital Advisors GP LLC, and Senai Asefaw, M.D. each beneficially own 2,873,555 shares, representing 4.9 percent of outstanding common stock.
In November 2025, Agios reported topline data from the global RISE UP Phase 3 trial of its pyruvate kinase (PK) activator in patients aged 16 years or older with sickle cell disease. The company intends to submit these results to the U.S. Food and Drug Administration for regulatory approval.
Financial and Strategic Analysis
Agios’ share price fell to $23.02 as of November 19, 2025, a 49.4 percent decline from its price one year prior. Average daily trading volume is approximately 654,700 shares, with 1.43 million shares traded on November 19. Key metrics as of the third quarter include:
| Metric | Value |
|---|---|
| Market Capitalization | $2.65 billion |
| Total Revenue (TTM) | $44.79 million |
| Net Loss (TTM) | $401.26 million |
| Cash and Cash Equivalents | $952.86 million |
| Total Debt/Equity (mrq) | 3.47 percent |
| Price/Book (mrq) | 2.05 |
| Enterprise Value/Revenue | 38.50 |
Negative earnings per share of –$7.01 and a leveraged free cash flow deficit of $313.98 million indicate ongoing investment in research and development. The company’s pipeline includes mitapivat and tebapivat (PK activators), AG-181 (PAH stabilizer for phenylketonuria), and other preclinical candidates targeting rare genetic disorders. Collaborative agreements, including a metabolic immuno-oncology alliance with Celgene established in 2016, are significant for Agios’ strategy regarding co-development and licensing revenue.
Market Position and Industry Context
Agios is recognized within the rare disease segment for its understanding of cellular metabolism and approaches to clinical development that involve patient engagement. The biopharmaceutical sector faces challenges such as regulatory scrutiny, competition for trial enrollment, and patent expirations. Agios distinguishes itself through its focused pipeline in hemolytic anemias, patient engagement programs, and strategic partnerships. The company's valuation and ongoing research and development expenditures highlight the importance of achieving successful clinical results and securing regulatory approvals to sustain its market position.
tl;dr
On November 19, 2025, Agios shares closed at $23.02, down 49.4 percent year-over-year. The company plans to submit its Phase 3 RISE UP trial data to the FDA following the topline results reported in November for sickle cell disease. Its October 30 filing reported third-quarter results, and a November 14 Schedule 13G/A disclosed key investors holding 4.9 percent of shares. With approximately $953 million in cash, Agios is positioned to support upcoming regulatory submissions and late-stage clinical trials into 2026.